服用低剂量雌二醇的变性女性的早期身体成分变化:使用双能吸收仪和生物电阻抗分析比较口服与舌下含服。

IF 3.3 3区 医学 Q1 UROLOGY & NEPHROLOGY
Iris Yaish, Assaf Buch, Guy Gindis, Yael Sofer, Mira Arbiv, Yaffa Moshe, Yona Grenman, Karen Tordjman
{"title":"服用低剂量雌二醇的变性女性的早期身体成分变化:使用双能吸收仪和生物电阻抗分析比较口服与舌下含服。","authors":"Iris Yaish, Assaf Buch, Guy Gindis, Yael Sofer, Mira Arbiv, Yaffa Moshe, Yona Grenman, Karen Tordjman","doi":"10.1093/jsxmed/qdaf005","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Low-dose sublingual estradiol gender-affirming hormone therapy (GAHT) in treatment-naive transgender women effectively suppresses testosterone and initiates breast development, comparable to oral estradiol with cyproterone acetate; however, its impact on body composition remains unstudied.</p><p><strong>Aim: </strong>To assess early body composition changes with low-dose estradiol, compare sublingual versus oral administration efficacy, and evaluate bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DXA) agreement in transgender women undergoing GAHT.</p><p><strong>Methods: </strong>In this 6-month prospective study, 22 treatment-naïve transgender women received either 2 mg/day sublingual estradiol (SLE) or combined oral (CO)-2 mg/day oral estradiol plus 10 mg/day cyproterone acetate. Body composition was assessed using DXA and BIA at baseline and after 6 months.</p><p><strong>Outcomes: </strong>Changes in body composition, including lean body mass, fat mass, visceral fat area, waist-to-hip ratio, and android-to-gynoid fat ratio.</p><p><strong>Results: </strong>BIA and DXA measurements showed good agreement. Both groups experienced decreased lean body mass and increased fat mass. The SLE group showed less increase in total and segmental body fat, and visceral fat area compared to CO. Both treatments decreased waist-to-hip ratio and android-to-gynoid fat ratio, indicating early achievement of a more feminine body shape.</p><p><strong>Clinical implications: </strong>These findings may help optimize GAHT protocols, improve patient satisfaction with treatment, and enable monitoring outcome assessment in transgender women.</p><p><strong>Strengths and limitations: </strong>This study provides valuable insights into early body composition changes with low-dose estradiol administration via different administration routes and validates BIA as an alternative to DXA. However, the sample size was relatively small, the study arm allocation was not randomized, and the study duration was only 6 months.</p><p><strong>Conclusion: </strong>Low-dose estradiol induces significant feminizing body composition changes within 6 months of GAHT, with sublingual administration potentially limiting fat accumulation while achieving a feminine body shape.</p><p><strong>Study registration: </strong>ISRCTN15726488 Entire data set found at:  https://doi.org/10.17605/OSF.IO/VNC54.</p>","PeriodicalId":51100,"journal":{"name":"Journal of Sexual Medicine","volume":" ","pages":"625-635"},"PeriodicalIF":3.3000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Early body composition changes in trans women on low-dose estradiol: comparing oral vs sublingual administration using dual energy absorptiometry and bioelectrical impedance analysis.\",\"authors\":\"Iris Yaish, Assaf Buch, Guy Gindis, Yael Sofer, Mira Arbiv, Yaffa Moshe, Yona Grenman, Karen Tordjman\",\"doi\":\"10.1093/jsxmed/qdaf005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Low-dose sublingual estradiol gender-affirming hormone therapy (GAHT) in treatment-naive transgender women effectively suppresses testosterone and initiates breast development, comparable to oral estradiol with cyproterone acetate; however, its impact on body composition remains unstudied.</p><p><strong>Aim: </strong>To assess early body composition changes with low-dose estradiol, compare sublingual versus oral administration efficacy, and evaluate bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DXA) agreement in transgender women undergoing GAHT.</p><p><strong>Methods: </strong>In this 6-month prospective study, 22 treatment-naïve transgender women received either 2 mg/day sublingual estradiol (SLE) or combined oral (CO)-2 mg/day oral estradiol plus 10 mg/day cyproterone acetate. Body composition was assessed using DXA and BIA at baseline and after 6 months.</p><p><strong>Outcomes: </strong>Changes in body composition, including lean body mass, fat mass, visceral fat area, waist-to-hip ratio, and android-to-gynoid fat ratio.</p><p><strong>Results: </strong>BIA and DXA measurements showed good agreement. Both groups experienced decreased lean body mass and increased fat mass. The SLE group showed less increase in total and segmental body fat, and visceral fat area compared to CO. Both treatments decreased waist-to-hip ratio and android-to-gynoid fat ratio, indicating early achievement of a more feminine body shape.</p><p><strong>Clinical implications: </strong>These findings may help optimize GAHT protocols, improve patient satisfaction with treatment, and enable monitoring outcome assessment in transgender women.</p><p><strong>Strengths and limitations: </strong>This study provides valuable insights into early body composition changes with low-dose estradiol administration via different administration routes and validates BIA as an alternative to DXA. However, the sample size was relatively small, the study arm allocation was not randomized, and the study duration was only 6 months.</p><p><strong>Conclusion: </strong>Low-dose estradiol induces significant feminizing body composition changes within 6 months of GAHT, with sublingual administration potentially limiting fat accumulation while achieving a feminine body shape.</p><p><strong>Study registration: </strong>ISRCTN15726488 Entire data set found at:  https://doi.org/10.17605/OSF.IO/VNC54.</p>\",\"PeriodicalId\":51100,\"journal\":{\"name\":\"Journal of Sexual Medicine\",\"volume\":\" \",\"pages\":\"625-635\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-04-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Sexual Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/jsxmed/qdaf005\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Sexual Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jsxmed/qdaf005","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:低剂量舌下雌二醇性别确认激素治疗(GAHT)对未接受治疗的跨性别女性有效抑制睾酮并促进乳房发育,与口服雌二醇加醋酸环丙孕酮相当;然而,它对身体成分的影响仍未得到研究。目的:评估低剂量雌二醇早期体成分变化,比较舌下给药和口服给药的疗效,并评估生物电阻抗分析(BIA)和双能x线吸收仪(DXA)在接受GAHT的跨性别女性中的一致性。方法:在这项为期6个月的前瞻性研究中,22名treatment-naïve变性女性接受了2 mg/天舌下雌二醇(SLE)或联合口服(CO)-2 mg/天口服雌二醇加10 mg/天醋酸环丙孕酮。在基线和6个月后使用DXA和BIA评估体成分。结果:身体组成的变化,包括瘦体重、脂肪量、内脏脂肪面积、腰臀比和雌雄脂肪比。结果:BIA和DXA测量结果吻合良好。两组都经历了瘦体重减少和脂肪增加。与CO相比,SLE组的总体脂和节段体脂以及内脏脂肪面积的增加较少。两种治疗均降低了腰臀比和雄激素与雌激素的脂肪比,表明早期实现了更女性化的体型。临床意义:这些发现可能有助于优化GAHT方案,提高患者对治疗的满意度,并使跨性别女性的监测结果评估成为可能。优势和局限性:本研究通过不同给药途径对低剂量雌二醇给药的早期体成分变化提供了有价值的见解,并验证了BIA可替代DXA。然而,样本量相对较小,研究分组不是随机分配的,研究持续时间只有6个月。结论:低剂量雌二醇在GAHT治疗6个月内诱导显著的女性化身体成分变化,舌下给药可能限制脂肪积累,同时实现女性化身材。研究注册:ISRCTN15726488完整数据集可在https://doi.org/10.17605/OSF.IO/VNC54找到。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Early body composition changes in trans women on low-dose estradiol: comparing oral vs sublingual administration using dual energy absorptiometry and bioelectrical impedance analysis.

Background: Low-dose sublingual estradiol gender-affirming hormone therapy (GAHT) in treatment-naive transgender women effectively suppresses testosterone and initiates breast development, comparable to oral estradiol with cyproterone acetate; however, its impact on body composition remains unstudied.

Aim: To assess early body composition changes with low-dose estradiol, compare sublingual versus oral administration efficacy, and evaluate bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DXA) agreement in transgender women undergoing GAHT.

Methods: In this 6-month prospective study, 22 treatment-naïve transgender women received either 2 mg/day sublingual estradiol (SLE) or combined oral (CO)-2 mg/day oral estradiol plus 10 mg/day cyproterone acetate. Body composition was assessed using DXA and BIA at baseline and after 6 months.

Outcomes: Changes in body composition, including lean body mass, fat mass, visceral fat area, waist-to-hip ratio, and android-to-gynoid fat ratio.

Results: BIA and DXA measurements showed good agreement. Both groups experienced decreased lean body mass and increased fat mass. The SLE group showed less increase in total and segmental body fat, and visceral fat area compared to CO. Both treatments decreased waist-to-hip ratio and android-to-gynoid fat ratio, indicating early achievement of a more feminine body shape.

Clinical implications: These findings may help optimize GAHT protocols, improve patient satisfaction with treatment, and enable monitoring outcome assessment in transgender women.

Strengths and limitations: This study provides valuable insights into early body composition changes with low-dose estradiol administration via different administration routes and validates BIA as an alternative to DXA. However, the sample size was relatively small, the study arm allocation was not randomized, and the study duration was only 6 months.

Conclusion: Low-dose estradiol induces significant feminizing body composition changes within 6 months of GAHT, with sublingual administration potentially limiting fat accumulation while achieving a feminine body shape.

Study registration: ISRCTN15726488 Entire data set found at:  https://doi.org/10.17605/OSF.IO/VNC54.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Sexual Medicine
Journal of Sexual Medicine 医学-泌尿学与肾脏学
CiteScore
6.20
自引率
5.70%
发文量
826
审稿时长
2-4 weeks
期刊介绍: The Journal of Sexual Medicine publishes multidisciplinary basic science and clinical research to define and understand the scientific basis of male, female, and couples sexual function and dysfunction. As an official journal of the International Society for Sexual Medicine and the International Society for the Study of Women''s Sexual Health, it provides healthcare professionals in sexual medicine with essential educational content and promotes the exchange of scientific information generated from experimental and clinical research. The Journal of Sexual Medicine includes basic science and clinical research studies in the psychologic and biologic aspects of male, female, and couples sexual function and dysfunction, and highlights new observations and research, results with innovative treatments and all other topics relevant to clinical sexual medicine. The objective of The Journal of Sexual Medicine is to serve as an interdisciplinary forum to integrate the exchange among disciplines concerned with the whole field of human sexuality. The journal accomplishes this objective by publishing original articles, as well as other scientific and educational documents that support the mission of the International Society for Sexual Medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信